Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21512962 | 1.00 | MAPT (0.49) | MAPTSLC40A1PIK3CGPIK3CDPIK3CA | |
| SCHEMBL3125256 | 0.82 | PIK3CG (0.61) | MAPTSLC40A1PIK3CGPIK3CDPIK3CA | |
| SCHEMBL858551 | 0.80 | SLC22A12 (0.42) | PIK3CGPIK3CDPIK3CAPIK3CBALDH1A1 | |
| SCHEMBL790162 | 0.80 | ALDH1A1 (0.51) | MAPTSLC40A1PIK3CGPIK3CDPIK3CA | |
| SCHEMBL807072 | 0.79 | GAA (0.49) | MAPTSLC40A1PIK3CGPIK3CDPIK3CA | |
| SCHEMBL22230597 | 0.79 | SLC40A1 (0.49) | MAPTSLC40A1PIK3CGPIK3CDPIK3CA | |
| SCHEMBL731743 | 0.79 | PIK3CD (0.70) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL358926 | 0.78 | PIK3CG (0.63) | SLC40A1PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL740383 | 0.76 | LMNA (0.53) | MAPTSLC40A1PIK3CGPIK3CDPIK3CA | |
| SCHEMBL789780 | 0.76 | PIK3CA (0.51) | MAPTSLC40A1PIK3CGPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | MAPT 2006/4885SLC40A1 4123/4885PIK3CG 1125/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | MAPT 2006/4885SLC40A1 4123/4885PIK3CG 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.